Alps Group posted a net loss of USD 2.09 million, narrowing from USD 2.62 million a year earlier.
Revenue rose 44% to USD 4.86 million, led by 51% growth in cellular therapy sales and a 20% increase in medical testing and aesthetics services.
Gross margin fell 6.5 percentage points to 32.1%, reflecting a shift toward aesthetic services with profit-sharing recorded in cost of sales.
Other operating income climbed to USD 1.33 million, driven by a USD 583,084 loan-modification gain and a USD 477,972 warrant-liability fair value gain.
Administrative expenses increased to USD 3.5 million, including USD 1.16 million of non-recurring De-SPAC professional fees tied to the Nasdaq listing.
ALPS•
